Main Disclosure – Disinvestment Details

Target Entity: MedTech division of Blue Star Engineering & Electronics Limited (Blue Star E&E), comprising the business of providing high-end medical diagnostic equipment and services.

Percentage Stake Disinvested: The entire MedTech division business is being sold as a going concern on a slump sale basis.

Post-Transaction Holding: Not applicable as this is a division sale, not a stake sale in a separate legal entity.

Counterparty/Buyer: Cyrix Healthcare Private Limited (Cyrix), described as a leading, pan-India Total MedTech Management Solutions provider with over 22 years of industry experience.

Mode of Consideration: Cash consideration of up to ₹40,00,00,000 (Rupees Forty Crores) as per the terms of the Business Transfer Agreement (BTA).

Valuation or Price Basis: The transaction is structured as a slump sale, with the consideration determined by the terms of the BTA.

Rationale for Disinvestment: The Business Transfer is being undertaken to focus on strategic priorities.

Impact on the Company:

  • The MedTech division contributed approximately 0.33% of the Company's consolidated income from operations for the financial year ended March 31, 2026.
  • The division's net worth was approximately ₹7.11 crores as of March 31, 2026, constituting around 0.21% of the Company's net worth.

Business Profile of Target Entity:

  • Sector: High-end medical diagnostic equipment and services (MedTech).
  • Financial Performance: The division's financials are integrated with Blue Star E&E's overall operations. Its net worth is not maintained or reported separately.
  • Operational Summary: The division was part of Blue Star E&E's comprehensive engineering solutions portfolio, which includes Data Security, MedTech, and Industrial Solutions.

Related Party Status: No. Cyrix Healthcare Private Limited is not part of the Promoter or Promoter Group of Blue Star Limited. The transaction does not fall within the ambit of related party transactions.

Approvals Required: The completion is subject to satisfactory fulfilment of conditions precedent, including obtaining all requisite approvals and completion of such procedures as may be required in accordance with the terms of the BTA.

Indicative Timeline: The slump sale is proposed to be completed by March 31, 2027.

Regulatory Context:

  • The transaction is outside the scope of any Scheme of Arrangement.
  • The provisions of Regulation 37A of the SEBI Listing Regulations are not applicable to this transaction.
  • The disclosure is made in compliance with Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Other Updates:

  • The Board meeting of Blue Star E&E was held on August 14, 2026, commencing at 6:15 p.m. and concluding at 6:45 p.m.
  • No other disclosures are present in the document.